A phase 2 study of minimal residual disease- guided, time-limited, first-line therapy of chronic lymphocytic leukemia with pirtobrutinib and venetoclax (MIRACLE)
LEUKEMIA & LYMPHOMA(2023)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要
LEUKEMIA & LYMPHOMA(2023)